Cardiotoxicity is one of the main adverse effects of the anti-cancer drugs, affecting the completion of treatment and both short-term and long-term quality of life. Cardio-oncology is an emerging medical field involved in prevention, detection, and treatment of cardiovascular effects from cancer therapy.
Our lab, which is part of the European ERA-NET consortium in Cardio-Oncology, combines medicinal chemistry, molecular and cellular biology and pharmacology to address the following objectives:
- 1- to develop new cardioprotective non-peptide agonists of prokineticin receptor 1 (PKR1),
- 3- to develop of novel diagnostic tools for cardiotoxicity,
- 4- to identify the molecular and cellular mechanisms controlling cardiac myogenesis, neovasculogenesis, and adipogenesis in hearts injured by anticancer drugs (anthracyclines, cisplatin, etc.).
Dr Canan Nebigil & Dr Laurent Désaubry, CNRS Research Directors, UMR 1260, INSERM-Université de Strasbourg, Regenerative Nanomedicine, CRBS, 1 rue Eugène Boeckel, 67000 Strasbourg, France – Phone : (+33) 388 391 228- e-mails : email@example.com & firstname.lastname@example.org